{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T22:12:52Z","timestamp":1772662372462,"version":"3.50.1"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:p>Amplification of <jats:italic toggle=\"yes\">HER-2<\/jats:italic> gene and overexpression of HER-2 receptor play a significant role in the progression of a number of malignancies such as breast cancer. Trastuzumab (anti-HER-2 therapeutic agent) has been used successfully in treatment of breast cancer. The aim of this study was to assess the pattern of <jats:italic toggle=\"yes\">HER-2<\/jats:italic> gene amplification and of HER-2 receptor expression in a spectrum of serous and mucinous ovarian tumors to determine whether HER-2 is altered in these neoplasms similar to that occurring in breast cancer. Formalin-fixed paraffin-embedded microarray tissue sections from 212 specimens were stained with HER-2 antibody using immunohistochemistry and with anti-HER-2 DNA probe using chromogenic in situ hybridization. Specimens consisted of 65 benign tumors (50 serous and 15 mucinous), 26 borderline (13 serous and 13 mucinous), 73 malignant tumors (53 serous carcinoma and 20 mucinous carcinoma), 18 metastatic deposits (13 serous and 5 mucinous), in addition to 30 normal tissues (16 ovarian surface and 14 normal fallopian tube). HER-2 protein\u2013positive expression was not detected in the normal or the benign tissues. Borderline neoplasms showed positive staining, but no overexpression. HER-2 overexpression was seen only in 4 carcinoma specimens: 1\/53 (1.8%) primary serous carcinomas and 3\/20 (15%) primary mucinous carcinomas. <jats:italic toggle=\"yes\">HER-2<\/jats:italic> gene amplification was seen in 4 specimens: 2 primary mucinous carcinomas and 2 malignant deposits of these 2 mucinous carcinomas. In conclusion, alteration of HER-2 was not detected in ovarian serous neoplasms; however, in mucinous carcinoma, <jats:italic toggle=\"yes\">HER-2<\/jats:italic> amplification and overexpression occur.<\/jats:p>","DOI":"10.1097\/pgp.0000000000000302","type":"journal-article","created":{"date-parts":[[2016,6,16]],"date-time":"2016-06-16T05:18:59Z","timestamp":1466054339000},"page":"50-57","source":"Crossref","is-referenced-by-count":13,"title":["Pattern of HER-2 Gene Amplification and Protein Expression in Benign, Borderline, and Malignant Ovarian Serous and Mucinous Neoplasms"],"prefix":"10.1097","volume":"36","author":[{"given":"Rabab A.A.","family":"Mohammed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rania","family":"Makboul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalia A.H.","family":"Elsers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek M.A.M.","family":"Elsaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abeer M.A.B.","family":"Thalab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar M.","family":"Shaaban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230824","first-page":"151","article-title":"Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications","volume":"27","author":"Kurman","year":"2008","journal-title":"Int J Gynecol Pathol"},{"issue":"suppl 2","key":"R2-20230824","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0893-3952(22)04456-8","article-title":"Origins and molecular pathology of ovarian cancer","volume":"18","author":"Bell","year":"2005","journal-title":"Mod Pathol"},{"key":"R3-20230824","first-page":"467","article-title":"Current issues in the pathology of ovarian cancer","volume":"50","author":"Rabban","year":"2005","journal-title":"J Reprod Med"},{"key":"R4-20230824","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","article-title":"The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory","volume":"34","author":"Kurman","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R5-20230824","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1210\/en.2011-2123","article-title":"Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy","volume":"153","author":"Romero","year":"2012","journal-title":"Endocrinology"},{"key":"R6-20230824","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1040-8428(01)00207-4","article-title":"HER-2 in breast cancer\u2014methods of detection, clinical significance and future prospects for treatment","volume":"43","author":"Rampaul","year":"2002","journal-title":"Crit Rev Oncol Hematol"},{"key":"R7-20230824","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1097\/MCG.0b013e31823457ea","article-title":"HER-2\/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients","volume":"46","author":"Liu","year":"2012","journal-title":"J Clin Gastroenterol"},{"key":"R8-20230824","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/sj.bjc.6601252","article-title":"The role of HER-2\/neu expression on the survival of patients with lung cancer: a systematic review of the literature","volume":"89","author":"Meert","year":"2003","journal-title":"Br J Cancer"},{"key":"R9-20230824","first-page":"1090","article-title":"The potential of monoclonal antibodies in cancer: established trastuzumab and cetuximab and promising targets IGF-1R and c-MET","volume":"25","author":"Bodmer","year":"2009","journal-title":"Med Sci"},{"key":"R10-20230824","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10585-014-9688-8","article-title":"T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2","volume":"32","author":"Nicoletti","year":"2015","journal-title":"Clin Exp Metastasis"},{"key":"R11-20230824","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1097\/IGC.0000000000000179","article-title":"Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model","volume":"24","author":"Yu","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"R12-20230824","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"R13-20230824","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"138","author":"Wolff","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"R14-20230824","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1158\/1078-0432.CCR-09-0449","article-title":"Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer","volume":"15","author":"Roepman","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R15-20230824","doi-asserted-by":"crossref","first-page":"R64","DOI":"10.1186\/bcr1770","article-title":"Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification","volume":"9","author":"Cayre","year":"2007","journal-title":"Breast Cancer Res"},{"key":"R16-20230824","first-page":"635","article-title":"Expression of HER2\/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary","volume":"14","author":"Karaferic","year":"2009","journal-title":"J BUON"},{"key":"R17-20230824","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/modpathol.2008.108","article-title":"Immunophenotyping of serous carcinoma of the female genital tract","volume":"21","author":"Nofech-Mozes","year":"2008","journal-title":"Mod Pathol"},{"key":"R18-20230824","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.acthis.2013.09.010","article-title":"Analysis of the contribution of immunologically-detectable HER2, steroid receptors and of the \u201ctriple-negative\u201d tumor status to disease-free and overall survival of women with epithelial ovarian cancer","volume":"116","author":"de Toledo","year":"2014","journal-title":"Acta Histochem"},{"key":"R19-20230824","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1525-1438.2001.011002119.x","article-title":"The growth factor receptors HER-2\/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma","volume":"11","author":"Skirnisdottir","year":"2001","journal-title":"Int J Gynecol Cancer"},{"key":"R20-20230824","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/IGC.0b013e31821e052e","article-title":"Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients","volume":"21","author":"Steffensen","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"R21-20230824","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/jso.23993","article-title":"Alteration in PI3K\/mTOR, MAPK pathways and Her2 expression\/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma","volume":"112","author":"Mahdi","year":"2015","journal-title":"J Surg Oncol"},{"key":"R22-20230824","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/PAS.0000000000000268","article-title":"Assessing the HER2 status in mucinous epithelial ovarian cancer on the basis of the 2013 ASCO\/CAP guideline update","volume":"38","author":"Chao","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R23-20230824","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1245\/s10434-011-1572-z","article-title":"Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer","volume":"18","author":"Lin","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"R24-20230824","doi-asserted-by":"crossref","first-page":"8121","DOI":"10.7314\/APJCP.2014.15.19.8121","article-title":"HER2 expression in ovarian mucinous carcinomas in Tunisia","volume":"15","author":"Missaoui","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"R25-20230824","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/1471-2407-9-433","article-title":"HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy","volume":"9","author":"McAlpine","year":"2009","journal-title":"BMC Cancer"},{"key":"R26-20230824","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/path.4088","article-title":"Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas","volume":"229","author":"Anglesio","year":"2013","journal-title":"J Pathol"},{"key":"R27-20230824","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/PAI.0b013e3181af7d3f","article-title":"Detection of HER-2 and EGFR gene amplification using chromogenic in-situ hybridization technique in ovarian tumors","volume":"18","author":"Lee","year":"2010","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R28-20230824","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/modpathol.2011.201","article-title":"Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH)","volume":"25","author":"Arnould","year":"2012","journal-title":"Mod Pathol"},{"key":"R29-20230824","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.breast.2005.09.008","article-title":"HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer\u2014a study of two hundred cases","volume":"15","author":"Saez","year":"2006","journal-title":"Breast"},{"key":"R30-20230824","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/modpathol.3800432","article-title":"Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility","volume":"18","author":"Gong","year":"2005","journal-title":"Mod Pathol"},{"key":"R31-20230824","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.lungcan.2009.05.002","article-title":"Reliability of chromogenic in situ hybridization for epidermal growth factor receptor gene copy number detection in non-small-cell lung carcinomas: a comparison with fluorescence in situ hybridization study","volume":"67","author":"Yoo","year":"2010","journal-title":"Lung Cancer"},{"key":"R32-20230824","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF03262077","article-title":"HER-2\/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival","volume":"5","author":"Kakar","year":"2000","journal-title":"Mol Diagn"},{"key":"R33-20230824","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/sj.bjc.6601200","article-title":"Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers","volume":"89","author":"Vernimmen","year":"2003","journal-title":"Br J Cancer"},{"key":"R34-20230824","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1101\/gad.1388706","article-title":"Derepression of the Her-2 uORF is mediated by a novel post-transcriptional control mechanism in cancer cells","volume":"20","author":"Mehta","year":"2006","journal-title":"Genes Dev"},{"key":"R35-20230824","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2003.10.104","article-title":"Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group","volume":"21","author":"Bookman","year":"2003","journal-title":"J Clin Oncol"},{"key":"R36-20230824","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ygyno.2014.09.003","article-title":"Targeting HER2 in ovarian and uterine cancers: challenges and future directions","volume":"135","author":"Teplinsky","year":"2014","journal-title":"Gynecol Oncol"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00004347-201701000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T01:22:59Z","timestamp":1692840179000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004347-201701000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000000302","relation":{},"ISSN":["0277-1691"],"issn-type":[{"value":"0277-1691","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}